Authors

Latest:

Why Oncologists Should Know More About Medical Marijuana

Increasingly, patients are asking oncologists for guidance and recommendations for the use of medical marijuana. However, finding those answers is challenging because of the federal government.

Bruce D. Rapkin, PhD

Latest:

Now is the Time to Improve Diversity in Cancer Clinical Trial

Fewer African American and Hispanic patients participated in oncology trials from 2003 to 2016 than from 1996 to 2002.

Andrew M. Evens, DO, MSc, FACP, Rutgers Cancer Institute of New Jersey

Latest:

Dr. Evens on the Design of a Retrospective Analysis Evaluating Salvage Regimens in R/R Hodgkin Lymphoma

Andrew M. Evens, DO, MSc, discusses the design of a retrospective analysis evaluating in relapsed/refractory classic Hodgkin lymphoma.

Samer A. Srour, MB ChB, MS

Latest:

Dr Srour on the Ongoing Investigation of CAR T-Cell Therapy in Advanced RCC

Samer A. Srour, MB ChB, MS, discusses the investigation of the allogeneic CAR T-cell therapy CTX131 in advanced clear cell renal cell carcinoma.

Morie A. Gertz, MD

Latest:

Dr Gertz on the Investigation of Birtamimab in Mayo Stage IV AL Amyloidosis

Morie A. Gertz, MD, discusses the rationale for the phase 3 AFFIRM-AL trial in patients with amyloid light chain amyloidosis and elaborates on the challenges that may arise when enrolling patients to this trial.

Gladys Giron, MD, FACS

Latest:

Reviewing Best Practices in the Surgical Management of Breast Cancer: Post-Surgery Outcomes in Stage IV Disease

In this final episode of OncChats: Reviewing Best Practices in the Surgical Management of Breast Cancer, Gladys Giron, MD, FACS, and Cristina Lopez-Peñalver, MD, shed light on clinical outcomes following surgery of the primary tumor in patients with stage IV breast cancer.

Sponsored Content by AbbVie Inc. and Genentech USA, Inc.

Andrea Billè, MD

Latest:

Dr Billè on the Use of Minimally Invasive Surgery vs Stereotactic Radiotherapy in NSCLC

Andrea Billè, MD, discusses findings from a propensity-matched comparison of minimally invasive surgery vs stereotactic ablative radiotherapy in patients with clinical stage I non–small cell lung cancer.

Michelle M. Le Beau, PhD

Latest:

Women in Oncology: Leukemia Therapies in Humans, for Humans

Judith Karp, MD, Azra Raza, MD, and Michelle M. Le Beau, PhD, discuss their proudest career accomplishments, including the investigation of potential treatments using a patient’s first cancerous cell, advances in cytogenetics, and a rational design for clinical trials involving cell cytokinetics..

Corinne Faivre-Finn, MD

Latest:

Dr Faivre-Finn on Areas of Debate Surrounding Concurrent Chemoradiotherapy Plus IO in LS-SCLC

Corinne Faivre-Finn, MD, discusses ongoing clinical debates regarding patient selection and optimal delivery of concurrent chemoradiotherapy followed by immunotherapy in LS-SCLC.

Nilofer Saba Azad, MD

Latest:

Dr. Azad on Selecting Between Regorafenib and TAS-102 in CRC

Nilofer Saba Azad, MD, discusses selecting between regorafenib and TAS-102 in colorectal cancer.

Salman R. Punekar, MD

Latest:

Dr Punekar on the Evaluation of NT-112 in KRAS G12D+ Advanced Solid Tumors

Salman R. Punekar, MD discusses the rationale for evaluating safety and preliminary anti-tumor activity of NT-112 in solid tumors with the KRAS G12D mutation.

Timothy Hughes, MD, MBBS, FRACP, FRCPA

Latest:

Dr Hughes on the Safety of Asciminib in Ph+ CP-CML

Timothy Hughes, MD, MBBS, FRACP, FRCPA, on safety data for asciminib in Philadelphia chromosome–positive chronic-phase chronic myeloid leukemia.

Sameh Gaballa, MD (Associate Member, Division of Malignant Hematology at Moffitt Cancer Center)

Justin Moyers, MD

Latest:

Dr. Moyers on Real-World Data With Adjuvant Immunotherapy in Melanoma

Justin Moyers, MD, discusses real-world data and sociodemographic factors from an early analysis of the National Cancer Database associated with the treatment of adjuvant immunotherapy in stage III melanoma.

Chad A. Hamilton, MD

Latest:

The Future of Ovarian Cancer Treatment

Oncologists contemplate what ovarian cancer treatment will look like in the future and exciting clinical trials in progress.

Sudeep Gupta, MBBS

Latest:

Dr. Gupta on the Use of Platinum Plus Standard Neoadjuvant Chemotherapy in TNBC

Sudeep Gupta, MBBS, professor, medical oncology, Tata Memorial Hospital, Mumbai, discusses key efficacy and safety data from a phase 3 trial of platinum plus standard neoadjuvant chemotherapy in operable, locally advanced triple-negative breast cancer.

Priya P. Chan, MD

Latest:

Expert Perspectives and Key Takeaways in pLGG Management

Experts discuss pediatric low-grade glioma (pLGG) as the most common childhood central nervous system (CNS) tumor, emphasizing a personalized, collaborative approach that integrates evolving molecular insights and patient factors to tailor treatments, improve quality of life, and offer hope through ongoing research and multidisciplinary care.

Yasser Mohamed Ali Ged, MBBS

Latest:

Dr Ged on the Background of the ORCHID Trial in BAP1-Mutated Metastatic RCC

Yasser Mohamed Ali Ged, MBBS, discusses the background of launching the phase 2 ORCHID trial evaluating olaparib monotherapy in patients with metastatic renal cell carcinoma harboring BAP1 or other DNA repair gene mutations.

Colin P. N. Dinney, MD

Colin P. N. Dinney, MD is the Chairman of the Department of Urology and a Professor in the Division of Surgery at The University of Texas M. D. Anderson Cancer Center.

Latest:

Dr Dinney on the Association Between UGDB and Cretostimogene Grenadenorepvec Response in NMIBC

Colin P.N. Dinney, MD, discusses urinary genomic disease burden as a potential biomarker for response to cretostimogene grenadenorepvec in bladder cancer.